A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N

Fredrik Sundquist; Kleopatra Georgantzi; Kirsten Brunsvig Jarvis; Jesper Brok; Minna Koskenvuo; Jelena Rascon; Max van Noesel; Per Grybaeck; Joachim Nilsson; Arthur Braat; Mikael Sundin; Sandra Wessman; Nikolas Herold; Lars Hjorth; Per Kogner; Dan Granberg; Mark Gaze; Jakob Stenman

doi:10.3389/fped.2022.836230

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N

Fredrik Sundquist, Kleopatra Georgantzi, Kirsten Brunsvig Jarvis, Jesper Brok, Minna Koskenvuo, Jelena Rascon, Max van Noesel, Per Grybaeck, Joachim Nilsson, Arthur Braat, Mikael Sundin, Sandra Wessman, Nikolas Herold, Lars Hjorth, Per Kogner, Dan Granberg, Mark Gaze, Jakob Stenman

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Artikkeli	836230
Lehti	Frontiers in pediatrics
Vuosikerta	10
Sivumäärä	11
ISSN	2296-2360
DOI - pysyväislinkit	https://doi.org/10.3389/fped.2022.836230
Tila	Julkaistu - 10 maalisk. 2022
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3123 Naisten- ja lastentaudit

Pääsy asiakirjaan

10.3389/fped.2022.836230

fped-10-836230Lopullinen julkaistu versio, 269 KBLisenssi: CC BY

Siteeraa tätä

Sundquist, F., Georgantzi, K., Jarvis, K. B., Brok, J., Koskenvuo, M., Rascon, J., van Noesel, M., Grybaeck, P., Nilsson, J., Braat, A., Sundin, M., Wessman, S., Herold, N., Hjorth, L., Kogner, P., Granberg, D., Gaze, M., & Stenman, J. (2022). A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N. Frontiers in pediatrics, 10, [836230]. https://doi.org/10.3389/fped.2022.836230

Sundquist, Fredrik ; Georgantzi, Kleopatra ; Jarvis, Kirsten Brunsvig ; Brok, Jesper ; Koskenvuo, Minna ; Rascon, Jelena ; van Noesel, Max ; Grybaeck, Per ; Nilsson, Joachim ; Braat, Arthur ; Sundin, Mikael ; Wessman, Sandra ; Herold, Nikolas ; Hjorth, Lars ; Kogner, Per ; Granberg, Dan ; Gaze, Mark ; Stenman, Jakob. / A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N. Julkaisussa: Frontiers in pediatrics. 2022 ; Vuosikerta 10.

@article{060016fb062b4530aaa86c5f223bc08b,

title = "A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N",

keywords = "neuroblastoma, refractory, Lu-& nbsp;177-DOTATATE, PRRT, radiopharmaceutical, high-risk, LOCAL-CONTROL, MOLECULAR RADIOTHERAPY, RADIATION-THERAPY, METASTATIC NEUROBLASTOMA, SOMATOSTATIN RECEPTORS, RADIONUCLIDE THERAPY, CHEMOTHERAPY, SURVIVAL, FEASIBILITY, OCTREOTIDE, Lu-177-DOTATATE, 3123 Gynaecology and paediatrics",

author = "Fredrik Sundquist and Kleopatra Georgantzi and Jarvis, {Kirsten Brunsvig} and Jesper Brok and Minna Koskenvuo and Jelena Rascon and {van Noesel}, Max and Per Grybaeck and Joachim Nilsson and Arthur Braat and Mikael Sundin and Sandra Wessman and Nikolas Herold and Lars Hjorth and Per Kogner and Dan Granberg and Mark Gaze and Jakob Stenman",

year = "2022",

month = mar,

day = "10",

doi = "10.3389/fped.2022.836230",

language = "English",

volume = "10",

journal = "Frontiers in pediatrics",

issn = "2296-2360",

publisher = "Frontiers Media SA",

}

Sundquist, F, Georgantzi, K, Jarvis, KB, Brok, J, Koskenvuo, M, Rascon, J, van Noesel, M, Grybaeck, P, Nilsson, J, Braat, A, Sundin, M, Wessman, S, Herold, N, Hjorth, L, Kogner, P, Granberg, D, Gaze, M & Stenman, J 2022, 'A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N', Frontiers in pediatrics, Vuosikerta 10, 836230. https://doi.org/10.3389/fped.2022.836230

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N. / Sundquist, Fredrik; Georgantzi, Kleopatra; Jarvis, Kirsten Brunsvig; Brok, Jesper; Koskenvuo, Minna; Rascon, Jelena; van Noesel, Max; Grybaeck, Per; Nilsson, Joachim; Braat, Arthur; Sundin, Mikael; Wessman, Sandra; Herold, Nikolas; Hjorth, Lars; Kogner, Per; Granberg, Dan; Gaze, Mark; Stenman, Jakob.

julkaisussa: Frontiers in pediatrics, Vuosikerta 10, 836230, 10.03.2022.

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N

AU - Sundquist, Fredrik

AU - Georgantzi, Kleopatra

AU - Jarvis, Kirsten Brunsvig

AU - Brok, Jesper

AU - Koskenvuo, Minna

AU - Rascon, Jelena

AU - van Noesel, Max

AU - Grybaeck, Per

AU - Nilsson, Joachim

AU - Braat, Arthur

AU - Sundin, Mikael

AU - Wessman, Sandra

AU - Herold, Nikolas

AU - Hjorth, Lars

AU - Kogner, Per

AU - Granberg, Dan

AU - Gaze, Mark

AU - Stenman, Jakob

PY - 2022/3/10

Y1 - 2022/3/10

KW - neuroblastoma

KW - refractory

KW - Lu-& nbsp;177-DOTATATE

KW - PRRT

KW - radiopharmaceutical

KW - high-risk

KW - LOCAL-CONTROL

KW - MOLECULAR RADIOTHERAPY

KW - RADIATION-THERAPY

KW - METASTATIC NEUROBLASTOMA

KW - SOMATOSTATIN RECEPTORS

KW - RADIONUCLIDE THERAPY

KW - CHEMOTHERAPY

KW - SURVIVAL

KW - FEASIBILITY

KW - OCTREOTIDE

KW - Lu-177-DOTATATE

KW - 3123 Gynaecology and paediatrics

U2 - 10.3389/fped.2022.836230

DO - 10.3389/fped.2022.836230

M3 - Article

VL - 10

JO - Frontiers in pediatrics

JF - Frontiers in pediatrics

SN - 2296-2360

M1 - 836230

ER -